LORICRIN and Alzheimer disease: Through STAT6 activation, IL-4 and IL-13 decrease the expression of key structural proteins like filaggrin, loricrin, and involucrin, and also impact the lipid content essential for skin barrier function, leading to increased trans-epidermal water loss (TEWL) that is a common marker for predicting AD [48,49].